Activation of EGFR, which enables cancer cells to bypass crizotinib-mediated inhibition of ROS1 signalling, has been described as a mechanism of resistance to crizotinib in ROS1-rearranged NSCLC [12]. The gene discussed is ROS1; the disease is cancer.